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Abstract
Background: Sildenafil and tadalafil are recommended firstline treatments for erectile dysfunction 
(ED). Sildenafil was legally reclassified to a ‘pharmacy’ medicine in the UK in 2018.
Aim: To assess the prescribing patterns and costs associated with prescribing of ED drugs in England, 
and to investigate the link between prescribing and deprivation, regional demography, and legal 
reclassification.
Design & setting: Analyses were conducted of publicly available government data from various 
sources pertaining to primary care prescribing and demographics in England.
Method: Prescribing and cost data from January 2009 to November 2019 were extracted and adjusted 
for inflation, male populations, and regional deprivation.
Results: Between 2009 and 2019 the rate of prescribing, measured as the number of items per 1000 
men, increased by 110%. In 2019, the rate of prescribing of ED medicines in the most deprived areas 
was 21.0% higher than the rate observed in least deprived areas. The northern regions of England 
approximately had a 50% higher rate of prescribing compared with London. A 1.3% annual increase 
in the number of prescription items was observed between 2018 and 2019 for Sildenafil, with a 5.8% 
increase observed from 2017–2018.
Conclusion: The two- fold increase in the rate of primary care prescriptions in the past 10 years suggests 
that more men are being screened for, or seeking help for, ED. The higher rate of prescribing offers 
opportunity for monitoring of linked risk factors, such as diabetes mellitus, dyslipidaemia, and vascular 
disorders, in deprived populations. Reclassification of sildenafil had a modest impact on prescribing 
practices.
How this fits in
There is a dearth of research in relation to presentation and management of ED in primary care, 
particularly in the UK. This study shows that over the past 10 years, there has been more than a two- 
fold increase in the rate of primary care prescriptions for ED, accounting for the changes in population. 
The reclassification of sildenafil as a pharmacy medicine in 2018 seemed to have modest impact on 
the prescribing trend. It is very likely that more men are being assessed for ED or seeking help in 
primary care in England. In addition, data suggest that prescribing is linked with deprivation. There is 
an opportunity in primary care for assessment of linked risk factors in men who present with symptoms.
Introduction
ED, ‘the persistent inability to achieve or maintain an erection that is sufficient to permit satisfactory 
sexual performance’, can affect the physical, emotional, and psychosocial health of the sufferer.1 ED can 
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have both an organic and psychogenic origin, and can be a risk marker for underlying cardiovascular 
diseases (CVDs) and mental health conditions, which may warrant further evaluation and treatment.2,3 
Medications, such as antihypertensives, antidepressants, and antipsychotics, can also lead to ED through 
their mechanisms of action.2 A systematic review reported that men with ED have an increased risk of 
all- cause mortality (odds ratio [OR] = 1.26; 95% confidence interval [CI] = 1.01 to 1.57) and CVD mortality 
(OR = 1.43; 95% CI = 1.00 to 2.05).4
The global prevalence of ED has been estimated to range from 3%–76.5%.4 A significant number 
of patients are known to suffer in isolation and do not seek help. Therefore, prevalence data are likely 
to be an underestimate.5 It is common for men with ED to experience anxiety, depression, relationship 
difficulties, and a lack of sexual confidence.2,3 These factors often lead to poorer quality of life for the 
sufferer, their partner, and family.
Both pharmacological and non- pharmacological treatment options are available for the treatment 
of ED. The National Institute for Health and Care Excellence (NICE) in England recommends using 
phosphodiesterase type- five inhibitors (PDE- 5I) as a firstline pharmacological treatment option for 
men with ED. Four PDE- 5Is are currently licensed in the UK and include sildenafil, tadalafil, vardenafil, 
and avanafil.5 However, only sildenafil and tadalafil remain the drugs of choice.
Sildenafil was reclassified in March 2018 by the UK’s Medicines and Healthcare products Regulatory 
Agency (MHRA) to ‘pharmacy- only’ medicine, which allowed community and online pharmacies to supply 
the drug to the patients without the need of a prescription.6 MHRA make decisions to alter the legal status 
of medicines in the UK from ‘prescription- only’ to ‘pharmacy’ or ‘general sales list’ categories (Table 1).7,8 
The decision to reclassify such medicines are primarily based on safety data.7 Such reclassifications are 
often expected to reduce the volume of prescribing and costs from the perspective of the NHS as patients 
are required to pay the price of the medicines at the point of purchase.
A cardiovascular risk assessment by a pharmacist in the community pharmacy is a prerequisite to 
pharmacy supply of sildenafil.9 Such risk assessment is undertaken using a series of questions asked to 
the patients before a supply can be made. Sildenafil is still available on NHS prescription along with 
tadalafil, vardenafil, and avanafil.
There is a lack of research in relation to presentation and management of ED in primary care, 
particularly in the UK. To date, no longitudinal research has looked into the prescribing patterns and 
costs of PDE- 5Is in English primary care settings. Given the association of ED with CVDs, including 
diabetes, vascular disorders, and mental health conditions,2,3,10 understanding any link that exists 
between deprivation and ED drugs prescribing trend will enable targeted interventions to manage 
comorbidities and reduce health inequality.
The primary aim of this study was to investigate the trend in quantity and cost of prescribing of 
sildenafil and tadalafil in primary care settings in England between 2009 and 2019. Specific objectives 
related to the investigation of: a) whether a prescribing trend of ED drugs is associated with deprivation 
and demography of various English geographical regions; and b) whether the legal reclassification of 
sildenafil to ‘pharmacy- only’ medicine has impacted on the trend in quantity and cost of prescribing 
of ED drugs in England.
Method
Study design
A secondary analysis of routinely collected data on the prescribing and dispensing of two ED drugs, 
sildenafil and tadalafil, within the NHS England primary care settings between January 2009 and 
November 2019, was conducted. This time period includes switches from patented medicines to 
generic drugs for both tadalafil and sildenafil, as well as the reclassification of sildenafil to ‘pharmacy- 
only’ medicine in March 2018.
Table 1 Legal classification of medicines in the UK
Prescription- only medicines (POM) Pharmacy (P) General sale list (GSL)
Available only under a prescription from 
a medical or a non- medical prescriber 
such as doctors, dentists, or a healthcare 
professional with an independent 
prescribing qualification and authority
Available under the supervision 
of a pharmacist from a pharmacy 
registered with the General 
Pharmaceutical Council (GPhC)
Available in general retail outlets 
such as supermarkets
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Data collection
Prescribing datasets were extracted from NHS Digital sources including  OpenPrescribing. net and 
Prescription Cost Analysis (PCA).11 These included data on the number of items prescribed, cost of 
prescribing, and prescribing patterns within specific clinical commissioning groups (CCGs) for both 
drugs. Data were adjusted for inflation using the Bank of England inflation calculator based on Office 
for National Statistics (ONS) composite price index.12 Data were also adjusted for male population 
estimates for each year.13 All data were extracted, independently checked for accuracy, and analysed 
using Microsoft Excel and IBM SPSS Statistics (version 21). Prescription patterns in the 10 most and 
the 10 least deprived CCGs as per the ONS Index of Multiple Deprivation (IMD) in 2015 (Table 2) were 
also extracted and analysed to explore the link between prescribing pattern and deprivation. The 
CCGs are clinically- led autonomous NHS bodies involved in planning and commissioning healthcare 
services for their locality. The 10 most deprived and the 10 least deprived CCGs covered a population 
of 1.38 million and 1.30 million, respectively.
Results
Number of items prescribed for ED increased by 110% between 2009 and 2019 (Figure 1). The increase 
in the number of items prescribed was mostly accounted for by sildenafil prescriptions, which increased 
by 165%. There were 2 145 393 items for ED prescribed in 2009 and 4 505 623 in 2019. The biggest 
year- on- year increase in the number of prescriptions was seen in 2014–2015, where an increase of 24% 
was observed.
The total items prescribed for sildenafil was relatively steady from 2009–2013, at around 48 items 
prescribed a year per 1000 men. The prescribing increased rapidly from 2013–2017. The highest 
yearly increase occurred from 2014–2015, which showed a 42.1% increase. A 5.8% yearly increase 
in the rate of prescription was observed between 2017 and 2018. A 0.5% increase in the rate of 
prescribing between 2018 and 2019 was observed, suggesting modest impact of reclassification on 
the prescribing practices. The number of items prescribed per 1000 men were 124.2 and 125.8 in 
2018 and 2019, respectively.
The spending on primary care prescriptions for ED decreased by 71.0% from £77.4 million in 2009 
to £22.4 million in 2019. The spending on sildenafil decreased by 90% and tadalafil decreased by 75%. 
The biggest decreases were seen after 2014 for sildenafil and 2018 for tadalafil (Figure 1).
Table 2 Top 10 most and least deprived CCGs in England according to the Index of Multiple Depri-
vation
10 most deprived CCGs
(relevant commissioning regions) IMD rank
10 least deprived CCGs
(relevant commissioning regions) IMD rank
NHS Bradford City CCG (North East and 
Yorkshire)
1 NHS Bracknell and Ascot CCG (South East) 200
NHS North Manchester CCG (North West) 2 NHS North East Hampshire and Farnham CCG 
(South East)
201
NHS Central Manchester CCG (North West) 3 NHS Windsor, Ascot and Maidenhead CCG 
(South East)
202
NHS Barking and Dagenham CCG (London) 4 NHS Chiltern CCG (South East) 203
NHS Sandwell and West Birmingham CCG 
(Midlands)
5 NHS Surrey Health CCG (South East) 204
NHS Blackpool CCG (North West) 6 NHS Horsham and Mid Sussex CCG (South 
East)
205
NHS City and Hackney CCG (London) 7 NHS Guildford and Waverley CCG (South East) 206
NHS Knowsley CCG (North West) 8 NHS Surrey Downs CCG (South East) 207
NHS Tower Hamlets CCG (London) 9 NHS Rushcliffe CCG (Midlands) 208
NHS Liverpool CCG (North West) 10 NHS Wokingham CCG (South East) 209
CCG = clinical commissioning group. IMD = Index of Multiple Deprivation.
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Deprivation and prescribing patterns
The most deprived regions consistently showed higher rates of prescriptions for ED drugs. In 2019 
there were 190.4 items prescribed per 1000 men of all ED drugs in the most deprived region. This 
figure was approximately 21.0% higher compared with the data from the least deprived regions, 
where a total of 150.5 items were prescribed per 1000 men.
In the most deprived regions, the yearly increases in prescription items were 9.0% in 2016, 4.5% 
in 2017, and 4.4% and 5.0% in 2018 and 2019, respectively. An overall 24.9% increase in prescription 
items was observed from 2015–2019. In the least deprived region, the rate of increase in the number 
of prescriptions was 38.9% during the same period (Figure 2).
Regional variations in prescribing
A wide variation in the rate of prescribing across the six English regions were observed. The North 
East and the North West regions had approximately 50% higher rates of prescribing compared with 
London. Rates of prescribing were 15.9, 15.3, and 10.3 items per 1000 men each month, respectively, 
in these regions (Figure 3).
Discussion
Summary
The aim of this study was to investigate the trend in prescribing of drugs for ED in primary care settings 
in England and to assess the impact of deprivation, regional demography, and legal reclassification of 
sildenafil on prescribing practices of ED drugs.
There was a persistent increase in the rate of prescribing for treatment of ED in men between 
2009 and 2019 in English primary care. Sildenafil remained the most frequently prescribed medication 
Figure 1 Volume and costs of prescribing for ED medicines from 2009–2019 in English primary care. ED = erectile dysfunction
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out of the two drugs of choice. A strong link between deprivation and prescribing trends were 
observed across all data points. These can be linked to higher prevalence of risk factors of ED, such as 
cardiovascular and mental health conditions, with deprivation.14 A north–south divide was observed 
in the rate of prescriptions, with higher prescribing rates observed in the northern regions of England 
compared with London and the southern regions. While some of the regional variations are explained 
by the differences in deprivation level, London’s younger population compared with the rest of the 
country15 could explain low ED prevalence and the observed low prescribing for ED. In addition, 
patient behaviours around use of online sources for access to sildenafil may be different across various 
geographical regions.
Data showed that reclassification of sildenafil to a pharmacy medicine from ‘prescription- only' 
medicine had modest impact on the trend of prescribing. It could be assumed that the reclassification 
of sildenafil would lead to a decrease in the number of items prescribed as people would be able 
to get their medicine directly from the pharmacy instead of needing to go to the doctors and wait 
for an appointment. It is important to note, however, that the pharmacy version of sildenafil costs 
approximately £20 for a pack of four tablets (as of April 2020) whereas the generic sildenafil prescriptions 
from a GP only costs £9 for the same number of tablets. The higher cost of the pharmacy version of 
the medicine compared with the prescription cost may dissuade patients from using pharmacy for 
accessing sildenafil. In addition, confidentiality and privacy have been cited as barriers to utilisation of 
sexual health services from pharmacy.16 The lack of long- term monitoring and follow- up in pharmacy 
settings may also discourage many patients from accessing the pharmacy version of sildenafil.
Strengths and limitations
This project included data from very large routinely collected datasets covering all primary care 
prescriptions in England. Deprivation data were based on CCG level and individual practice level 
variations were not accounted for. This study only included NHS prescription data and private 
Figure 2 The number of items of ED medicines prescribed annually in the most and least deprived CCGs in England. CCG = clinical commissioning 
groups. ED = erectile dysfunction
Bell C et al. BJGP Open 2021; DOI: 10.3399/bjgpopen20X101145
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prescriptions were not accounted for. Only two PDE- 5Is were included, sildenafil and tadalafil, as 
the authors' observations suggested that the rest of the PED- 5Is accounted for negligible volume 
of prescribing and, hence, did not impact on the trend analysis. Similarly, community and online 
pharmacy sales of over- the- counter sildenafil were not included in the trend analysis. Some patients 
may avoid perceived embarrassment and confidentiality issues in face- to- face clinical consultations 
in primary care and community pharmacy16 by accessing medicines through online sources. Other 
available treatments for ED, including vacuum- pump treatment and psychosexual therapies, were not 
included in the study. In addition, prevalence data of ED over time were considered for this study. 
The segmented regression for different policy changes (for example, sildenafil patent expiry in June 
2013, tadalafil patent expiry in November 2017, and reclassification of sildenafil from prescription 
medicine to pharmacy medicine in March 2018) could not be performed owing to: a) absence of 
monthly prescribing and spending data (access was restricted to annual level for historical data prior 
to 2015); and b) inadequate time- points before and after different policy changes needed to conduct 
segmented regression analysis.17
Comparison with existing literature
There is a lack of literature on the prescribing and management of ED in primary care. Previous 
studies have reported that many men do not seek help with sexual problems to avoid perceived 
embarrassment for themselves and their doctors.18,19 The observed increasing trend in the rate of 
prescriptions may have been contributed by various factors. These include inclusion of ED assessment 
for men with diabetes in the Quality and Outcomes Framework (QOF) since 2013–2014.20 The QOF 
required opportunistic screening, advice and assessment of contributory factors, and treatment 
options for ED in patients with diabetes in primary care. In addition, media, including social media, 
may have contributed to increased knowledge and awareness of the condition among members of the 
general public given the licensing of newer PDE- 5Is in recent years.
The study shows that the introduction of generic versions of both sildenafil in 2013 and tadalafil 
in 2017 reduced overall spending on drugs used for ED. The expiry of the patent on sildenafil in 
June 2013 allowed the NHS to purchase generic sildenafil from other pharmaceutical companies 
Figure 3 The number of erectile dysfunction medicine items prescribed per month in each NHS commissioning region in 2018 and 2019
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for a competitive price, subsequently reducing the price per item from £31.31 in 2012 to £2.53 in 
2014.11 This also allowed sildenafil to be removed from the Selected List Scheme, which restricted 
prescriptions of certain drugs in May 2014, allowing more men access to the medicine on the NHS, 
which potentially increased the number of items prescribed.21 The patent on tadalafil also expired in 
November 2017, leading to a 49% decrease in cost per item from £49.40 in 2017 to £25.12 in 2018.
Implications for research and practice
The data suggest that more men are seeking help or being assessed for ED in primary care. The 
increased presentations and, hence, prescribing for EDs allows further opportunities to screen 
for the associated risk factors for ED. These include: CVDs such as hypertension, coronary artery 
disease, peripheral vasculopathy; endocrine disorders such as diabetes, metabolic syndrome, and 
hyperthyroidisim; as well as assessment of psychogenic risk factors and medication- induced ED.2 
Prescribers should be aware of the wider organic, psychogenic nature and linked risk factors of ED 
including diabetes, vascular disorders, and mental health conditions. The cause of ED needs to be 
established before treatment can commence and patients should be referred to specialist clinics where 
appropriate. Guidelines recommend that a physical examination, including genitourinary, endocrine, 
vascular, and neurological systems, is undertaken. This can reveal any unsuspected diagnoses, such as 
Peyronie’s disease, pre- malignant or malignant genital lesions, prostatic enlargement or irregularity 
or nodularity, or signs and symptoms suggesting hypogonadism.2,3 It is, however, unclear how often 
patients are screened for the red- flag symptoms. Long- term safety outcomes of PDE- 5Is are not 
understood. Prescribers should, therefore, reassess the continuous use of these drugs on a periodic 
basis.22,23
Reclassification to allow ‘pharmacy- only’ supply of drugs to free- up GP time and resources have faced 
successes and barriers in the past.24–26 For example, reclassification of drugs such as chloramphenicol 
eye products, mild steroids, and antifungal products have been positively received by patients, GPs, 
and pharmacists. However, reclassified pharmacy version of simvastatin was not adopted in practice to 
the same extent.24 Research on community pharmacist and patient perspectives on the need, supply, 
and aspects of risk assessments and referrals are warranted. GPs and patient experiences of access to 
sildenafil from pharmacy also need to be further explored.
Results of this study suggest that more men are being screened for, or seeking help with, ED. The 
two- fold observed increase in the population adjusted rate of prescriptions over the past 10 years is 
less likely to be accounted for by other factors. Promotion of sildenafil by pharmaceutical industries 
since being made available over the counter for pharmacy sales could have raised awareness of 
ED among the general public. Higher rate of prescribing in deprived regions offers opportunity for 
monitoring of linked health conditions such as CVD and diabetes. Reclassification of sildenafil to 
pharmacy medicine had a modest impact on prescribing practices.
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